Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage.

JACC Basic Transl Sci · 2025 · PMC11830260 · PMID 39958474

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally significantP = 0.05actually significant

At 2 hours after reperfusion, EMPA pretreatment led to a significant reduction of MMP-2 and a marginally significant increase ( P = 0.05) in TIMP-1 protein levels, whereas no alterations were detected in ICAM-1 ( Figures 6E and 6G ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.